Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.
This article was originally published in PharmAsia News
Executive Summary
Takeda is gearing up for a 2010 launch of the orphan bone cancer immunotherapy Mepact (mifamurtide) in Europe and is considering re-submitting its failed U.S. FDA application for that compound, after buying IDM Pharma for $75 million in a deal announced May 18You may also be interested in...
AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme
AMAG Pharmaceuticals announced April 1 it would team up with Takeda Pharmaceutical to commercialize its intravenous iron drug Feraheme (ferumoxytol) outside the US. A deal was not unexpected, as AMAG has signaled since winning approval from U.S. FDA in 2009 that the best way to maximize growth of Feraheme, especially in the European Union, is with a partner with global reach
AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme
AMAG Pharmaceuticals announced April 1 it would team up with Takeda Pharmaceutical to commercialize its intravenous iron drug Feraheme (ferumoxytol) outside the US. A deal was not unexpected, as AMAG has signaled since winning approval from U.S. FDA in 2009 that the best way to maximize growth of Feraheme, especially in the European Union, is with a partner with global reach
Takeda Shifts Resources In U.S. For "Promotionally Sensitive" Brands
TOKYO - Takeda Pharmaceutical Feb. 3 reported a 53.7 percent net earnings jump for the April-December 2009 period from the same period a year ago as it was released from the drag of its Millennium Pharmaceutical acquisition costs, but - as has affected all Japanese pharma - sales of its core projects were generally soft because of the yen's rise against the U.S. dollar
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: